Vela Diagnostics today announced a collaboration with France's Gustave Roussy Institute of Oncology on next-generation based cancer testing.

The collaboration will focus on both solid and liquid tumor diagnostics using Vela's Sentosa NGS platform. Gustave Roussy, located just outside Paris, recently implemented the Sentosa platform to diagnose melanoma, colorectal cancer, and non-small cell lung cancer.

The collaboration is the latest positive development for Singapore-based Vela. In September, the firm resumed operations as it exited judicial management — a legal process similar to Chapter 11 bankruptcy. Vela had ceased normal operations upon entering the process in early 2015.